London Stock Exchange · Healthcare
Invest in Hikma Pharmaceuticals stock from India
Indian and foreign residents can buy Hikma Pharmaceuticals (HIK) shares directly through Paasa.
By Paasa · Updated
Hikma Pharmaceuticals at a glance
- Price
- £15.90-£0.35 (2.15%)
- Market cap
- £3.32B
- Day range
- £15.78 – £16.28
- P/E
- 11.77
- Dividend yield
- 3.99%
- Volume
- 264.75K
- 1 month
- -2.33%
- 6 months
- +27.92%
- YTD
- +2.58%
- 1 year
- -4.16%
- 5 years
- -34.16%
Hikma Pharmaceuticals statements, FY2021–FY2025
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $3.3B | $3.1B | $2.9B | $2.5B | $2.6B |
| Gross profit | $1.4B | $1.4B | $1.4B | $1.3B | $1.3B |
| Operating income | $579.9M | $612.0M | $367.0M | $591.0M | $634.0M |
| Net income | $410.4M | $359.0M | $190.0M | $188.0M | $421.0M |
| Earnings per share | $1.86 | $1.61 | $0.85 | $0.84 | $1.82 |
| EBITDA | $845.0M | $787.0M | $791.0M | $485.0M | $744.0M |
| Total assets | $5.7B | $5.1B | $4.7B | $4.5B | $4.4B |
| Total debt | $1.6B | $1.3B | $1.2B | $1.3B | $846.0M |
| Cash and short-term investments | $354.1M | $213.0M | $229.0M | $292.0M | $450.0M |
| Shareholders' equity | $2.6B | $2.3B | $2.2B | $2.1B | $2.5B |
| Operating cash flow | $366.5M | $564.0M | $608.0M | $530.0M | $638.0M |
| Free cash flow | $165.4M | $399.0M | $439.0M | $392.0M | $493.0M |
| Capital expenditure | −$201.1M | −$165.0M | −$169.0M | −$138.0M | −$145.0M |
Fiscal years as reported, the latest ending 31 Dec 2025. Figures in USD; a dash means the provider reported nothing for that line.
Peer comparison
| Company | Ticker | Price | Market cap |
|---|---|---|---|
| ConvaTec | CTEC.L | £2.09 | £408.21B |
| HUTCHMED (China) | HCM.L | £2.16 | £187.72B |
| Uniphar | UPR.L | £3.36 | £87.22B |
| Allergy Therapeutics | AGY.L | £0.05 | £30.08B |
| Beximco Pharmaceuticals | BXP.L | £0.58 | £25.65B |
| Animalcare | ANCR.L | £3.35 | £23.13B |
| ECO Animal Health | EAH.L | £0.99 | £6.57B |
| Shield Therapeutics | STX.L | £0.05 | £5.56B |
Peers as grouped by the data provider. This is not an investment recommendation.
How to invest in Hikma Pharmaceuticals from India
Step 1
Open your Paasa account
KYC takes a few minutes: PAN, Aadhaar and address proof. Your brokerage account is opened in your own name with Interactive Brokers.
Step 2
Add funds from your Indian bank account
Remit up to $250,000 a year under the RBI's Liberalised Remittance Scheme. Your bank converts the rupees to US dollars at its rate on the day you remit, and Interactive Brokers converts the dollars to GBP when you buy.
Step 3
Search HIK and buy
Find Hikma Pharmaceuticals by name or by its ticker, HIK, and place your order.
Why invest in Hikma Pharmaceuticals from India
What Hikma Pharmaceuticals does
Hikma Pharmaceuticals PLC is a global pharmaceutical enterprise involved in the creation, production, promotion, and distribution of a wide array of generic, branded, and licensed medicinal solutions. These offerings are presented in various dosage formats, including solid, semi-solid, liquid, and injectable forms. Hikma Pharmaceuticals operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector.
Paasa handles the paperwork
Investing abroad brings paperwork with it: remittance filings, capital gains reporting, foreign asset disclosure. Paasa prepares all of it for you. Your India-ready tax reports arrive at year end, ready to file.
Here's what inheritance rules in the UK mean for your Hikma Pharmaceuticals shares.
Shares in UK-incorporated companies are UK-situs assets and fall within UK Inheritance Tax, charged at 40% above the £325,000 threshold for non-residents.
Frequently asked questions
Can I buy Hikma Pharmaceuticals stock from India?
Yes. Indian residents and NRIs can buy Hikma Pharmaceuticals (HIK) shares directly through Paasa. Hikma Pharmaceuticals is listed on the London Stock Exchange, in the Drug Manufacturers - Specialty & Generic industry. Your money leaves India under the RBI's Liberalised Remittance Scheme and the shares are held in your own name at Interactive Brokers.
How are Hikma Pharmaceuticals dividends taxed for Indian investors?
The UK levies 0% withholding tax on company dividends paid to non-residents. Dividends are taxed at your slab rate in India. Hikma Pharmaceuticals’ current yield is 3.99%. Paasa's dividend report lists the gross dividend and any tax withheld for each payment, which is what you need when you file.
What tax do I pay in India when I sell Hikma Pharmaceuticals shares?
Non-residents are exempt from UK capital gains tax on the disposal of listed shares. In India, gains on shares held for more than 24 months are long-term and taxed at 12.5%, and gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate. Both are worked out in rupees at the GBP/INR rate on the day you bought and the day you sold, so the currency move is part of the gain. Paasa's capital-gains statement gives you the figures for your return.
What happens to my Hikma Pharmaceuticals shares if I pass away?
Shares in UK-incorporated companies are UK-situs assets and fall within UK Inheritance Tax, charged at 40% above the £325,000 threshold for non-residents. The rule looks at everything you hold there, not at Hikma Pharmaceuticals alone.
Is there stamp duty when I buy Hikma Pharmaceuticals shares?
The UK charges 0.5% Stamp Duty Reserve Tax when buying direct company shares electronically on the LSE; ETFs and UCITS funds do not attract it.